Otros idiomas Cerevel Therapeutics Holdings, Inc.

Acciones

CERE

US15678U1280

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
42,47 ^USD	+0,95 %		+0,62 %	+0,17 %

18/04	El medicamento para la enfermedad de Parkinson de Cerevel Therapeutics alcanza el objetivo principal en un estudio de fase tardía	RE
18/04	Cerevel Therapeutics anuncia resultados topline positivos para el tavapadon en un ensayo adyuvante de fase 3 para personas que viven con la enfermedad de Parkinson	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease	19/04
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	18/04
Cerevel Therapeutics' Potential Parkinson's Treatment Meets Primary Endpoint in Phase 3 Study	18/04
Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study	18/04
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease	18/04
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson?s Disease	18/04
Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation	25/03
Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,057,890, According to a Recent SEC Filing	04/03
Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Sector Update: Health Care Stocks Gain Late Afternoon	22/02
AbbVie Plans $13 Billion Bond Sale to Fund Acquisitions	22/02
Phew! The party continues!	22/02
AbbVie eyes selling at least $13 bln of bonds to fund M&A, Bloomberg reports	22/02
North American Morning Briefing : Stock Futures -2-	21/02
AbbVie CEO to Retire; COO Robert Michael Named Successor	20/02
BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase	13/02
AbbVie Completes $10.1 Billion Acquisition of ImmunoGen, Lowers Q1 Adjusted EPS Guidance	12/02
AbbVie 4Q Sales Lower as Himura Revenue Sinks	02/02
Omzetdaling Abbvie valt mee	02/02
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals	02/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Cerevel Therapeutics Holdings, Inc.

Acciones

CERE

US15678U1280

Otros idiomas

Filtros